Last reviewed · How we verify
n-acetylcystine
N-acetylcystine, marketed by Assiut University, holds a niche position in the pharmaceutical market with its unique mechanism of action. The drug's key strength lies in its composition patent, which is set to expire in 2028, providing a period of exclusivity and protection against generic competition. The primary risk is the lack of clear revenue data and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | n-acetylcystine |
|---|---|
| Also known as | acetylcystein, Mucomyst, NAC, acetylcystine |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of NAC on Symptoms of CHR Patients (NA)
- Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine (PHASE4)
- Glutathione in Mild Cognitive Impairment (EARLY_PHASE1)
- A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis. (PHASE4)
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial (PHASE3)
- N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use (PHASE4)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- n-acetylcystine CI brief — competitive landscape report
- n-acetylcystine updates RSS · CI watch RSS
- Assiut University portfolio CI